Intraductal tubulopapillary neoplasm (ITPN) of the pancreas associated with an invasive component: a case report with review of the literature

Stefanie Kuscher 1*, Hartmut Steinle 2, Afschin Soleiman 3, Dietmar Öfner 1, Stefan Schneeberger 1 and Georg Oberhuber 3

Abstract

Background: Intraductal tubulopapillary neoplasm (ITPN) depicts a distinct entity in the subgroup of premalignant epithelial tumors of the pancreas. Although the histomorphological and immunophenotypical characterization of ITPN has been described by several authors in terms of report of case series in the past, the rarity of that tumor subtype and similarity to other entities still makes identification of ITPN a challenge for radiologists and pathologists. To date, little is known about tubulopapillary carcinoma that can evolve from ITPN.

Case presentation: In the present work, we analyze one case of ITPN associated with an invasive component and discuss the results involving the current literature. Collected patient data included medical history, clinical symptoms, laboratory tests, radiological imaging, reports of interventions and operation, and histopathological and immunohistochemical examinations. The patient initially presented with acute pancreatitis. A solid tumor obstructing the main pancreatic duct and sticking out of the papilla of Vater was detected and caught via endoscopic intervention. Histopathological examination of the specimen revealed mainly tubular growth pattern with back to back tubular glands. Immunohistochemically, the tumor was strongly positive for keratin 7 (CK7) and pankeratin AE1/AE3, and alpha 1 antichymotrypsin; negative for synaptophysin and chromogranin A, CDx2, CK20, S100, carcinoembryonic antigen (CEA), MUC 2, MUC5AC, and somatostatin; and in part positive for CA19-9. Extended pancreatoduodenectomy was performed, the final diagnosis was tubulopapillary carcinoma grown in an ITPN.

Conclusion: The identification of an ITPN of the pancreas can be a challenging task. Endoscopic retrograde cholangiopancreatography is an excellent tool to directly see and indirectly visualize the intraductal solid tumor and to take a biopsy for histopathological evaluation at the same time. Together with a thorough immunohistochemical workup, differential diagnoses can be ruled out quickly. To date, reports of ITPN are rare and little is known about the potential for malignant transformation and the prognosis of tubulopapillary carcinoma grown from an ITPN. Radical surgical resection following oncologic criteria is recommended; however, more data will be needed to assess an adequate treatment and follow-up standard.

Keywords: Intraductal, Pancreas, Neoplasia, Carcinoma, Pancreatoduodenectomy
**Background**

Intraductal tubulopapillary neoplasm was first recognized by Japanese investigators [1]. In 2002, the Japan Pancreas Society proposed the name intraductal tubular carcinoma which was in 2009 changed to intraductal tubulopapillary neoplasm. In 2010, the World Health Organization (WHO) recognized intraductal tubulopapillary neoplasms (ITPNs) of the pancreas as a distinct entity which was included in the subgroup of premalignant epithelial tumors of the pancreas. It was defined as intraductal, grossly visible, tubule-forming epithelial neoplasm with high-grade dysplasia and ductal differentiation without overt production of mucin.

In the current edition of the WHO tumor classification, only ITPN and intraductal pancreatic mucinous neoplasm (IPMN) are included in the category intraductal neoplasms. Other entities which may histologically mimic ITPN and may show intraductal growth such as acinar cell carcinoma and pancreatic neuroendocrine tumor are not included in this category, as they show a nonductal differentiation.

ITPN is a rare tumor and accounts for less than 1% of exocrine pancreatic neoplasms. It usually appears as a solid mass obstructing the main pancreatic duct thereby causing upstream duct dilation. Due to its malignant potential, ITPN is usually treated by radical surgical resection following oncological criteria in a curative approach [2]. Pylorus-preserving pancreaticoduodenectomy is one of the most frequently performed surgical procedures for that purpose, as ITPNs are known to be located in the head of the pancreas in up to 50%.

Whereas histopathological and immunohistochemical characteristics are well described, little is known about surgical outcome and prognosis of ITPN to date.

**Case presentation**

The 73-year-old male patient initially presented in the emergency room with nausea and persistent abdominal pain in the upper right quadrant for 1 day. He reported to feel weak and exhausted for a few weeks already. A weight loss of 5 kg in 2 months was attributed to a special diet; the patient did not record loss of appetite. Night sweating was negated. The medical history did not reveal a malignant or benign disease of the gastrointestinal tract. A routinely performed screening colonoscopy 3 years ago showed normal findings.

Elevation of serum amylase and lipase, liver transaminases, and bilirubin as well as the patient’s clinical presentation indicated acute pancreatitis (Table 1).

Contrast-enhanced computed tomography (CT) of the abdomen confirmed the diagnosis of pancreatitis, showing edematous peripancreatic fat, minimal amounts of ascites, accentuated peripancreatic lymph nodes, a dilated pancreatic duct in the tail and body of the pancreas, and slightly dilated intra- and extrahepatic bile ducts. There were no clear signs of a tumor or stenosing process in the pancreas and bile ducts at that time (Fig. 1).

Conservative treatment and further evaluation including endosonography and endoscopic retrograde cholangiopancreatography (ERCP) were initiated. Endosonography revealed an enlarged pancreatic head with inhomogeneous parenchyma, compromising the distal bile duct, but without signs of mechanic cholestasis or cholelithiasis. The pancreatic duct was dilated to 7 mm (Fig. 2), with a vaguely discernible configuration of the duct wall, being suspicious of main-duct-intraductal pancreatic mucinous neoplasm (IPMN). ERCP showed an atypical tissue fragment sticking out of the swollen orifice of the papilla of Vater, considered either to be a thrombus, sludge, or neoplasm (Fig. 3). With minimal manipulation, the specimen dropped into the duodenum and could be collected for histopathological examination (Fig. 4). Bile duct intubation was unsuccessful. Pancreatography revealed congestion of the distal duct, a protective plastic stent was therefore inserted, and an aspirate probe was taken for cytological evaluation (Figs. 5 and 6). During the procedure, the examiner did not notice mucin content.

Histopathological and immunohistochemical workup (antibodies listed in Table 2) of the specimen collected via endoscopy yielded the unexpected diagnosis of a partly necrotic, highly differentiated pancreatic tumor, strongly positive for keratin 7 (CK7) and pankreatin AE1/AE3, and alpha 1 antichymotrypsin; negative for synaptophysin and chromogranin A, CDx2, CK20, S100, MUC 2, MUC5AC, carcinoembryonic antigen (CEA), and somatostatin; and in part positive for CA19-9 (20%...
of cells positive). A proliferation rate of 20% was revealed by Ki-67 staining. CK7 expression in combination with the histological feature of a tumor with back to back tubular glands was indicative of intraductal tubulopapillary neoplasia. In the absence of desmoplastic stroma reaction, classic pancreatobiliary carcinoma was considered unlikely. A neuroendocrine tumor was excluded due to the negative immunohistological reaction to neuroendocrine markers.

Cytological evaluation of the pancreatic duct aspirate was performed in an extern laboratory. The probe did not contain any cells or mucin and was D-PAS negative. KRAS mutation was not detected. The patient was checked for abnormality of serum immunoglobulins, in particular IgG4 and tumor markers, but showed no relevant increase of alpha-1-fetoprotein, CEA, cancer antigen (CA) 19-9, CA72-4, CA125, IgA, IgM, or IgE. Only IgG subclass 2 was unspecifically elevated.

Eighteen days after the initial endoscopic intervention with pancreatic stenting, re-endoscopy with stent removal and follow-up endosonography were performed. Pancreatic duct diameter had normalized. A highly suspect 11-mm hypoechoic vascularized lesion with sharp limitation, contacting but not compromising the pancreatic duct, was detected in the pancreatic body. In the inhomogenously structured pancreatic head, pancreatitis seemed to have regressed, but a hypoechoic formation without a clear border was seen, suspicious of pancreatic carcinoma. The distal common bile duct was compressed in the pancreatic head with a slight prestenotic dilatation.

Staging CT of the chest, abdomen, and pelvis confirmed the presence of a suspect hypodense lesion located in the head of the pancreas (Fig. 7), and
accentuated peripancreatic, mesenteric, and parailiac lymph nodes with a maximum diameter of 8 mm were described. There was no indication of metastatic tumor spread. Magnetic resonance cholangiopancreaticography (MRCP) was not performed.

Following interdisciplinatory consensus in the hepatopancreato-biliary tumor conference, oncologic extended pylorus-preserving pancreaticoduodenectomy (PPPD) was planned. After another short episode of a mild pancreatitis and thorough anaesthesiological evaluation prior to surgery, extended PPPD with pancreatogastric anastomosis was performed without complications on day 47 after initial admission to hospital. Intraoperative immediate frozen sections of the resection margins of the common bile duct and pancreas were free of tumor cells. Intraoperative sonography of the liver showed no sign of hepatic tumor spread.

In the formalin-fixed surgical specimen, macroscopy revealed a narrowed pancreatic duct in a distance of 1 cm from the papilla, occluded by a drop-shaped 8-mm tumor that appeared to leave the duct wall intact for the most part. The organ parenchyma appeared partly fibrous with regular acini in the uncinate process.

Histopathological examination of HE-stained sections taken form most parts of the resection specimen revealed an intraductal lumen-occluding lesion with a mainly tubular growth pattern with back to back tubular glands (Figs. 8 and 9). In areas with intraductal growth, a remainder of the original ductal epithelium was observed in some ducts. Nodular tumor cell aggregates showing the same histomorphological appearance were seen extraductally (Fig. 10). Those nodules infiltrated the normal

Table 2 Antibodies for immunohistochemistry

| Target antigen | Provider | Article number | Dilution | Clone   |
|----------------|----------|----------------|----------|---------|
| CK AE1/AE3     | DAKO     | GA053          | RTU      | AE1/AE3 |
| Antichymotrypsin| Menarini | 44421          | 1:80     | Polyclonal |
| Synaptophysin  | DAKO     | IR660          | RTU      | DAK-SYNAP |
| Chromogranin A | DAKO     | M0869          | 1:200    | DAK-A3 |
| CDx2           | DAKO     | GA080          | RTU      | DAK-CDX2 |
| CK20           | DAKO     | GA777          | RTU      | KS208 |
| CK7            | DAKO     | GA619          | RTU      | OV-TL 12/30 |
| CK19           | DAKO     | GA615          | RTU      | RCK108 |
| S100           | DAKO     | GA504          | RTU      | Polyclonal |
| CEA            | DAKO     | GA622          | RTU      | II-7 |
| Somatostatin   | DAKO     | A0566          | 1:200    | Polyclonal |
| CA 19.9        | DAKO     | M5317          | 1:70     | 1116-NS-19-9 |
| Ki-67          | DAKO     | GA626          | RTU      | MIB-1 |
| MUC2           | DAKO     | IR658          | RTU      | CCP58 |
| MUC5AC         | DAKO     | IR661          | RTU      | CLH2 |

The antibodies used for the specific molecular characterization of ITPN and distinction from other entities are listed above. RTU ready to use.

Fig. 5 After the specimen has been removed, intubation of the papilla can be performed for pancreatography.

Fig. 6 A 7-French plastic stent is placed into the congested distal pancreatic duct in order to drain the dilated duct of the pancreatic body and tail.

Fig. 7 Contrast-enhanced CT in portal venous phase shows the hypodense lesion in the pancreatic head.
pancreatic tissue, reaching the organ margins without invasion of the peripancreatic fatty tissue. The remaining parenchyma was fibrotic with signs of chronic pancreatitis. Immunohistology revealed the same findings as compared to the biopsy specimen including a strong expression of keratin 7 by all tumor cells (Fig. 11). Neuroendocrine markers (synaptophysin, chromogranin A) were negative as was a trypsin stain. Keratin 19 was positive in approximately 10% of tumor cells.

Definite histopathological diagnosis was a tubulopapillary carcinoma of the pancreatic head grown from an intraductal tubulopapillary neoplasm with a maximal tumor diameter of 28 mm.

According to the Union for International Cancer Control (UICC) 8th edition TNM staging for malignant tumors, the tumor was classified as pT2, pN0 (0/25), L0, V0, Pn0, R0 (wide), which refers to a stage IB. The tumor was considered low-grade (G1) [3].

The patient could be discharged from hospital on postoperative day (POD) 13 after an uneventful postoperative course. Six weeks after the operation, on POD 43, the patient was readmitted for 1 day due to unspecific upper abdominal pain and vertigo. Clinical examination showed a distended abdomen, but no signs of peritonitis. Abdominal sonography revealed slightly reduced bowel movements. There were no signs of cholestasis or fluid collections seen on ultrasound examination. Blood test showed normal levels of serum pancreatic and liver enzymes as well as normal inflammation parameters (Table 3). Regular postoperative findings were recorded on abdominal CT. After fast recovery under conservative treatment with bland diet and analgetics, the patient could be discharged in good general condition.

Due to the rarity of that specific tumor entity and data postulating lower malignancy than in ductal adenocarcinoma, the interdisciplinary tumor conference decided for short interval follow-up (3 months) without adjuvant chemotherapy.

The patient recently had the second follow-up in our hepatopancreatobiliary outpatient clinic 6 months after pancreatic resection. Physical examination as well as blood tests and abdominal sonography showed normal findings, and the patient presented clinically well under pharmacological pancreatic enzyme substitution. The next follow-up appointment after three more months is planned to include an abdominal CT.
Discussion and conclusion
Intraductal tubulopapillary neoplasm (ITPN) depicts a rare subgroup of intraductal epithelial neoplasms of the pancreas. Yamaguchi et al. were the first ones to collect and describe 10 cases of that previously undefined type of tumor [1]. In the 4th edition of WHO tumor classification in 2010, ITPN was then determined one distinct entity of premalignant epithelial tumors of the pancreas besides IPMN, PanIN grade 3, and mucinous cystic neoplasm.

ITPN most commonly shows the morphological appearance of a solid nodular tumor arising in the main pancreatic duct and obstructing the ducts with subsequent upstream dilatation [1]. Consistent with that, our patient showed a polypous lesion sticking out of the papilla of Vater, causing pancreatic duct obstruction and dilatation and reactive pancreatitis. Due to unspecific symptoms such as discomfort, abdominal pain, and weight loss, the lesion is often only detected incidentally on abdominal imaging examination [4]. A discrimination between ITPN and IPMN based on imaging findings in abdominal sonography, endosonography, CT and magnetic resonance imaging (MRI) techniques, and endoscopic retrograde cholangiopancreatographic (ERCP) can be challenging, as both entities show similar properties [2, 5]. In 2012, Motosugi and colleagues published a synopsis on radiomorphological features of 11 histologically confirmed ITPN in 10 patients, 9 of whom belonged to the study population of Yamaguchi’s first report of ITPN [1, 6]. On contrast-enhanced CT, low density of the ITPN lesion compared to the adjacent pancreatic parenchyma was detected in arterial, portal venous, and delayed phase. Agreeing with that, our patient’s tumor presented as hypodense formation in the pancreatic head on contrast-enhanced CT (pancreatic parenchyma phase). In six out of seven patients that underwent MRI, signal intensity of ITPN was low in T1-weighted MRI and high in T2-weighted MRI. Moreover, Motosugi postulated intraductal tumor growth could be detected best on endoscopic or transabdominal ultrasonography [6]. A two-tone duct sign was frequently seen on MRCP and ERCP, meaning a pancreatic duct that appears in two colors, one of the dilated pancreatic duct and one of the intraductal tumor. Once the mass fills the duct lumen, an abrupt disruption is seen. If the tumor does not obstruct the duct and hence is surrounded by pancreatic fluid, a cork of wine bottle sign can be described. However, the retrospective study design and non-uniform radiologic examination of patients in multiple institutions, as well as the lacking comparison to
imaging of other pancreatic neoplasms, clearly limit the conclusions to be taken from this study [6].

Typical features of ITPN on histopathological examination are a tubulopapillary growth pattern, high-grade dysplasia, necrotic foci, and a lack of visible intracellular mucin, which distinguish ITPN from IPMN [1]. In contrast, acinar cell carcinoma, neuroendocrine tumor, and in biopsy specimens also, solid pseudopapillary neoplasm, may show similar histopathologic features and cannot be distinguished in conventional histology. However, a differing immunohistological pattern allows the distinction of those entities [7]. In our case, the lack of the neuroendocrine markers synaptophysin and chromogranin ruled out a pancreatic neuroendocrine tumor. The strong expression of CK7 in combination with negative trypsin stain militated against acinar cell carcinoma. The histomorphological features were not compatible with a solid pseudopapillary neoplasm.

Regarding immunohistochemical appearance, ITPN was reported lacking gastroenteric differentiation, typically seen in IPMN, reflected by the absence of MUC2 (and of CDX2) and MUC5AC expression. Instead, signs of pancreatic duct differentiation are revealed by expression of CK7 and/or CK19, as well as MUC1 and MUC6 [2, 4, 5, 8–12]. A large series of ITPN (n = 33) recently reported by Basturk et al. focused on a thorough clinicopathological characterization of those uncommon pancreatic lesions. Data from five high-volume centers of surgical pathology were collected and reviewed for that purpose. Besides the aforementioned characteristics, the authors noticed CAM5.2 labeling of all ITPNs, as a proof of epithelial tissue origin, and the absence of MUC2 and MUC5AC [4].

Date et al. screened the literature for reports on ITPN in 2016 and retrospectively analyzed a total of 58 cases, including Yamaguchi’s first cases [2]. In their summary of immunohistochemical features of ITPN, they also reported that CK7 and CK19 were typically positive while trypsin, MUC2, and MUC5AC were negative. The absence of the neuroendocrine markers synaptophysin and chromogranin A, another suggestive fact on the diagnostic pathway, was recorded in their own ITPN case. In 2015, Muraki et al. published their workup of an intraductal neoplasm showing typical clinical and histomorphological features of an ITPN but exhibiting MUC5AC expression and hence impeding the discrimination between ITPN and pancreatobiliary-type IPMN [13]. The authors appealed on a more precise classification of those neoplastic lesions. Another Japanese group emphasized the importance of a thorough characterization and the publication of each precisely described ITPN case in order to gain more detailed information about that rare entity [14]. They recently published their own case of an ITPN that showed the classic immunomorphological phenotype with expression of CK7 and CK19, and negativity for MUC2 and MUC5AC. The lesion occupied the entire pancreas with intraductal growth and infiltration of the main pancreatic duct, and total pancreatectomy with splenectomy was required [14].

MUC5AC has been found to be expressed commonly by pancreatic ductal adenocarcinoma (PDAC) and, less frequently, by precursor lesions such as IPMN [15–17]. As mentioned above, ITPN typically does not express MUC5AC. Some authors noted that MUC5AC expression on pancreatic ductal adenocarcinoma (PDAC) comes along with better outcome, meaning higher survival rates, compared to MUC5AC-negative PDAC [18, 19]. On the other hand, it has been shown in experimental models that MUC5AC aids cancer cells escape from the immune system and is therefore associated with poor outcome [20]. Investigations on the mucine profile of pancreatic neoplasms are being performed to explore the value of MUC5AC expression and other mucines as prognostic markers and potential therapeutic targets [15, 21–23].

ITPN show genetic patterns that are different from those seen in IPMN, PanIN, and pancreatic ductal adenocarcinoma, specifically an absence of KRAS and BRAF mutations [1, 2, 4, 8, 11]. Yamaguchi et al. worked up 14 ITPNs and 15 IPMNs of the gastric-type, pyloric gland variant (IPMN-PG), in order to explore and compare the two entities’ molecular genetic fingerprints. They found KRAS mutations in only 1 ITPN but in 12 IPMN-PGs. BRAF mutation was detected in 1 ITPN but in none of the IPMN-PGs, and GNAS mutation was evident in none of the 14 ITPNs but in 9 of 15 IPMN-PGs [24]. The prevalence of KRAS and GNAS mutations in IPMNs as well as the typical absence of KRAS mutation in ITPNs was described by other groups as well [25].

### Table 3: Postoperative blood test results

| Postoperative day (POD) | Pancreas alpha-amylose (13–53 U/l) | Lipase (13–60 U/l) | ALT (10–50 U/l) | AST (10–50 U/l) | gGT (10–71 U/l) | AP (40–130 U/l) | Bilirubin (0–1.28 mg/dl) | CRP (0–0.5 mg/dl) | WBC (4–10 G/l) |
|------------------------|-----------------------------------|-------------------|-----------------|-----------------|-----------------|-----------------|----------------------|----------------|---------------|
| POD 12                 | 6                                 | 6                 | 48              | 25              | 87              | 104             | 0.26                 | 2.17           | 5.9           |
| POD 43                 | 25                                | 29                | 31              | 23              | 30              | 95              | 0.39                 | 0.07           | 6.0           |
| POD 102                | –                                 | –                 | 23              | 25              | 47              | 114             | 0.33                 | 0.35           | 3.6           |
| POD 193                | –                                 | –                 | 24              | 21              | 99              | 168             | 0.45                 | 0.74           | 3.5           |

Laboratory findings at different time points are shown in Table 2. Liver and pancreatic enzymes and parameters of cholestasis and inflammation were normal when the patient was readmitted on POD 43 due to abdominal discomfort.
Recently, Basturk et al. published their thorough workup including genomic analyses of 22 ITPN cases. The authors postulate that the distinct genetic characteristics they could show in ITPN and IPMN might serve as specific targets for innovative therapeutic means in the future [26].

Intraductal tubulopapillary neoplasms have also been reported to occur in the bile ducts [27, 28]. Nakagawa et al. found an intraductal neoplasia in an intrahepatic bile duct, showing similar histological and immunohistochemical features as ITPN of the pancreas [29]. Investigations on 20 bile duct ITPNs in 2015 revealed the high prevalence of an invasive carcinoma component (80%) but with a 5-year survival rate of 90% pointing to a less-aggressive malignancy compared to other epithelial carcinomas in that region [28].

Addressing the need for early detection and discrimination of different pancreatic lesions, Tajima et al. reflected the value of endoscopic ultrasound-guided fine needle aspiration cytology (EUS-FNAC) and described their observations in one case [30]. Three conspicuous findings were recorded on cytological examination: papillary cellular clusters with branching, tubules in contact with fibrovascular structures and cribriform structures. Loose cohesiveness of constituent cells was observed. Individual cells showed relatively uniformly enlarged nuclei with parachromatin clearing and distinct nucleoli. Morphological appearance and lack of cytoplasmic mucin lead to the suspected diagnosis of ITPN with a carcinoma component. After radical surgical resection, histopathological workup of the specimen revealed the same morphological patterns as seen in cytological examination and confirmed the diagnosis of ITPN [30]. EUS-FNAC was postulated a valuable diagnostic tool by other authors as well. The presence of thin fibrovascular structures surrounded by tubules and cribriform structures in ITPN are considered important cytological features to distinguish ITPN from IPMN [30–32]. More precisely, Aslan and colleagues emphasized the presence of highly cellular three-dimensional clusters showing complex branching, tubular and cribriform patterns, the absence of true papillary structures containing a fibrovascular core, and the absence of intracytoplasmic mucin, as well as uniformly enlarged nuclei with distinct nucleoli and scarcity of mitosis as typical features shown by ITPN [31]. Tajima et al. came to the conclusion that the typical three-dimensional clusters and tubules in contact with fibrovascular structures are detectable by FNAC and possibly by pancreatic duct brushing cytology, but not in cytological examination of pancreatic fluid [30].

Unspecific symptoms such as discomfort, abdominal pain, weight loss, and jaundice due to pancreatic duct obstruction may be recorded in ITPN patients [11]. In their study population, Basturk et al. recorded no specific disease-related symptoms in 18 (54.5%) out of 33 patients.

In the study reported by Basturk et al., 45% of ITPN were located in the head of the pancreas, 32% in the body/tail, and 23% diffusely involved the organ [4], agreeing with Kölby's observation of 52% of ITPN located in the pancreatic head, 17% in the body, 7% in the tail, 3% in both head and body, and 14% in the whole pancreas [11]. Rooney et al. reported pancreatic head and pylorus-preserving pancreateodudenectomy to be the most commonly performed therapeutic procedure for ITPN in a curative attempt [9]. The patient we present also showed tumor growth in the pancreatic head and underwent extended pancreaticoduodenectomy following oncologic criteria. On the surgical specimen, maximum tumor diameter of 2.8 cm was measured. Basturk et al. quoted a median tumor size of 4.5 cm, and within the tumor mass, both cystic and solid regions were described. In their literature review and collection of 30 ITPN cases, Kölby et al. recorded a median tumor diameter of 3 cm.

A significant proportion of ITPN may become invasive [4]. The invasive component may be morphologically similar to the intraductal one or may be highly infiltrative resembling conventional ductal carcinoma. Whereas the ductal carcinoma like invasive tumor is easily recognized, this is not the case with the tumors showing a tubulopapillary pattern. Invasive parts of the ITPN form round aggregates that closely resemble areas with intraductal growth. Invasiveness can only be determined by carefully examining the borders of the aggregates, which may be slightly irregular. Also, invasive areas are always devoid of remaining duct cells, which are often found in intraductal growing parts of the tumor. Finally, the distribution of the aggregates, which are observed in areas devoid of ducts, aids in the diagnosis of invasiveness. In our case, the invasive component was exclusively similar to the intraductal one. This fact readily explains the findings in radiology and ultrasound, which were not considered specific for invasive ductal carcinoma of the pancreas.

In the study of Kölby et al., one patient died from multiple liver metastases after 7 months, two other patients had successful treatment for tumor recurrence 12 and 34 months postoperatively, and two patients required palliative care for recurrent disease with distant metastases after 18 and 24 months [11]. The authors pointed out that recurrence may have been caused by intraductal colonization after distal pancreatectomy. However, distal pancreatectomy may be saved in a considerable proportion of patients as demonstrated by the disease-free survival in others that underwent distal pancreatectomy.

In the study by Basturk et al., follow-up data of 22 patients were available. Among those, the 5-year survival rate was 100% in patients without an invasive component and 71% in patients with an invasive carcinoma. Two patients died of the disease at 23 and 41 months;
one patient died of unrelated causes at 49 months. After a median follow-up period of 61.5 months, 12 patients were alive with disease, while 7 patients were disease-free after a median follow-up of 19 months [4]. When Date et al. collected published data from patients surgically treated for ITPN of the pancreas in order to determine outcome, they reported 37 cases in whom an overall postoperative 5-year survival rate of 80.7% was detected. However, the value of those results is clearly limited since the authors included cases from the era before diagnostic guidelines for ITPN were defined [2]. Anyway, several authors postulated a relatively favorable overall outcome after curative resection compared to conventional pancreatic ductal adenocarcinoma [4, 8, 9, 12].

Satisfying results have been shown after radical resection of pancreatic ITPN, compared to the more malignant course of PDAC. Following oncologic R0 resection, our patient did not show any sign of disease recurrence in the short postoperative period of 6 months. The interdisciplinary tumor board decided for initial 3-monthly follow-up in our specialized hepatopancreatobiliary surgery outpatient unit. Close clinical follow-up is recommended for early detection of disease recurrence [11].

To date, reports of ITPN with or without invasive carcinoma are rare and case series largely make recourse to earlier publications. In order to assess the long-term outcome of ITPN and to develop appropriate therapeutic strategies, more data will be needed in the future.

Abbreviations
CEA: Carcinoembryonic antigen; CT: Computed tomography; ERCP: Endoscopic retrograde choledangiopancreatography; EUS-FNAC: Endoscopic ultrasound-guided fine needle aspiration cytology; IPMN: Intraductal papillary mucinous neoplasia; ITPN: Intraductal tubulopapillary neoplasm; MRI: Magnetic resonance imaging; PanIN: Pancreatic intraepithelial neoplasia; PDAC: Pancreatic ductal adenocarcinoma; PPPD: Pylorus-preserving pancreaticoduodenectomy; WHO: World Health Organization

Acknowledgements
Not applicable

Funding
Not applicable

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. In terms of a literature review, PubMed database was searched for relevant publications on ITPN (openly available). All patient-related data including medical history, imaging, histopathological findings, surgery reports, laboratory tests, and discharge letters are drawn in retrospect from our hospital’s electronic patient database. Only medical personnel with relation to the patient’s medical case has access to those data.

Authors’ contributions
SK acquired all patient data regarding the pancreatic disease, performed literature research, interpreted the results, and wrote most part of the article. HS was the first physician in charge (internal medicine) who performed diagnostic ERCP and was case manager in the tumor board. SS and DO were the patient’s surgical case managers; SS did the pancreas operation (senior) with assistance of SK (trainee). GO and AS performed the histopathological and immunohistochemical examinations of the pancreas specimens; GO was involved in the writing process, acting as a mentor for SK. All authors read and approved the final manuscript.

Author’s information
The first author, Stefanie Kuscher, is a surgical resident with special interest in pancreas pathologies, respectively pancreas surgery, and a research focus on those topics.

Ethics approval and consent to participate
Not applicable

Consent for publication
The patient was informed about the intention to publish a report of his medical case including anonymized images, without publication of personal data such as name, date of birth, or address. All questions could be answered in the conversation and the patient personally signed the consent form.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria. 2Department of Internal Medicine I, Gastroenterology and Hepatology, Medical University of Innsbruck, Innsbruck, Austria. 3Pathology Department of the General Hospital of Innsbruck, Innsbruck, Austria.

Received: 30 August 2017 Accepted: 7 November 2017
Published online: 16 November 2017

References
1. Yamaguchi H, Shimizu M, Ban S, Koyama I, Hatori T, Fujita I, Yamamoto M, Kawamura S, Kobayashi M, Ishida K, et al. Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2009;33:1164–72.
2. Date K, Okabayashi T, Shima Y, Iwata J, Sumiyoshi T, Kozuki A, Morita S, Hata Y, Noda Y, Nishioka A, Matsumoto M. Clinicopathological features and surgical outcomes of intraductal tubulopapillary neoplasm of the pancreas: a systematic review. Langenbeck’s Arch Surg. 2016;401:439–47.
3. Briere JD. TNN classification of malignant tumours: John Wiley & Sons; 2017.
4. Basturk O, Adsay V, Askan G, Dhall D, Zamboni G, Shimizu M, Cymes K, Cameiro F, Balci S, Sigel C, et al. Intraductal tubulopapillary neoplasms of the pancreas: a clinicopathologic and immunohistochemical analysis of 33 cases. Am J Surg Pathol. 2017;41:313–25.
5. Del Chiaro M, Mucelli RP, Blomberg J, Segersvård R, Verbeke C. Is intraductal tubulopapillary neoplasia a new entity in the spectrum of familial pancreatic cancer syndrome? Familial Cancer. 2014;13:227–9.
6. Motosugi U, Yamaguchi H, Furukawa T, Ichikawa T, Hatori T, Fujita I, Yamamoto M, Motoi F, Kanno A, Watanabe T, et al. Imaging studies of intraductal tubulopapillary neoplasms of the pancreas: 2-tone duct sign and cork-of-wine-bottle sign as indicators of intraductal tumor growth. J Comput Assist Tomogr. 2012;36:710–7.
7. Chelliah A, Kalimuthu S, Chetty R. Intraductal tubular neoplasms of the pancreas: an overview. Ann Diagn Pathol. 2016;24:68–72.
8. Ahls MG, Niedergethmann M, Dinter D, Sauer C, Lüttges J, Post S, Marx A, Gaiser T. Case report: Intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype. Diagn Pathol. 2014;9:11.
9. Rooney SL, Shi J. Intraductal tubulopapillary neoplasm of the pancreas: an update from a pathologist’s perspective. Arch Pathol Lab Med. 2016;140:1068–73.
10. Bhuvu N, Wasan H, Spalding D, Stamp G, Harrison M. Intraductal tubulopapillary neoplasm of the pancreas as a radiation induced malignancy. BMJ Case Rep. 2011;2011
11. Kolby D, Thélén J, Andersson R, Saso A, Ansari D. Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature. Int J Clin Exp Pathol. 2015;8:672–80.

12. Kasugai H, Tajiri T, Takehara Y, Mukai S, Tanaka J, Kudo SE. Intraductal tubulopapillary neoplasms of the pancreas: case report and review of the literature. J Nippon Med Sch. 2013;80:224–9.

13. Muraki T, Uehara T, Sano K, Oota H, Yoshizawa A, Asaka S, Tateishi A, Otsuki T, Shingu K, Matoba H, et al. A case of MUC5AC-positive intraductal neoplasm of the pancreas classified as an intraductal tubulopapillary neoplasm? Pathol Res Pract. 2015;211:1034–9.

14. Fujimoto Y, Tomimaru Y, Tamura H, Noguchi K, Nagase H, Hamabe A, Hirota M, Oshiria K, Tanida T, Kawase T, et al. Pancreatic intraductal tubulopapillary neoplasm with associated invasive cancer successfully treated by total pancreatectomy: a case report. Oncol Lett. 2017;14:153–8.

15. Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepato-Biliary-Pancreat Surg. 2002;9:328–41.

16. Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, Yonezawa S. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepato-Biliary-Pancreat Surg. 2007;14:243–54.

17. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Goto M. Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Sci. 2010;17:108–24.

18. Jinfeng M, Kimura W, Hirai I, Sakurai F, Moriya T, Mizutani M. Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis. Int J Gastrointest Cancer. 2009;34:9–18.

19. Yonezawa S, Horinouchi M, Sato E. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int. 1999;49:45–54.

20. Hoshi H, Sawada T, Uchida M, Saito H, Iijima H, Toda-Agetsuma M, Wada T, Yamazoe S, Tanaka H, Kimura K, et al. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int J Oncol. 2011;38:619–27.

21. Higashi M, Yokoyama S, Yamamoto T, Goto Y, Kitazono I, Hirota M, Taguchi H, Hashimoto S, Fukukura Y, Koriyama C, et al. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Pancreas. 2015;44:728–34.

22. Kanno A, Satoh K, Kimura K, Hirota M, Umino J, Masumune A, Satoh A, Asakura T, Egawa S, Sunamura M, et al. The expression of MUC4 and MUC5AC is related to the biologic malignancy of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2006;33:391–6.

23. Torres MP, Chakraborty S, Souchek J, Batra SK. Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des. 2012;18:2472–81.

24. Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Furukawa T. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. J Pathol. 2013;231:335–41.

25. Klöppel G, Basturk O, Schlichter AM, Konukiewitz B, Esposito I. Intraductal neoplasms of the pancreas. Semin Diagn Pathol. 2014;31:452–66.

26. Basturk O, Berger MF, Yamaguchi H, Aidsay V, Askan G, Bhakot UK, Zehir A, Carneiro F, Hong SM, Zamboni G, et al. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. Mod Pathol. 2017. doi:10.1038/modpathol.2017.60.

27. Kataki N, Torres J, Klimstra DS. Intraductal tubular neoplasms of the bile ducts. Am J Surg Pathol. 2012;36:1647–55.

28. Schlichter AM, Jang KT, Klöppel G, Saka B, Hong SM, Choi H, Offerhaus GJ, Hruban RH, Zen Y, Konukiewitz B, et al. Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol. 2015;28:1249–64.

29. Nakagawa T, Arisaka Y, Ajiki T, Fujikura K, Masuda A, Takenaka M, Shimoi H, Okabe Y, Fukumoto T, Ku Y, et al. Intraductal tubulopapillary neoplasm of the bile duct: a case report and review of the published work. Hepatol Res. 2016;46:713–8.

30. Tajima S. Intraductal tubulopapillary neoplasm of the pancreas suspected by endoscopic ultrasonography-fine-needle aspiration cytology: report of a case confirmed by surgical specimen histology. Diagn Cytopathol. 2015;43:1003–6.

31. Aslan DL, Jessurun J, Gulbahce HE, Pambuccian SE, Aidsay V, Mallery JS. Endoscopic ultrasound-guided fine needle aspiration features of a pancreatic neoplasm with predominantly intraductal growth and prominent tubular cytomorphology: intraductal tubular carcinoma of the pancreas? Diagn Cytopathol. 2008;36:833–9.